A detailed history of Roberts Glore & CO Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Roberts Glore & CO Inc holds 30,442 shares of ABBV stock, worth $5.42 Million. This represents 1.76% of its overall portfolio holdings.

Number of Shares
30,442
Previous 32,850 7.33%
Holding current value
$5.42 Million
Previous $5.63 Million 6.69%
% of portfolio
1.76%
Previous 1.72%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$163.84 - $199.33 $394,526 - $479,986
-2,408 Reduced 7.33%
30,442 $6.01 Million
Q2 2024

Aug 14, 2024

SELL
$154.79 - $180.76 $113,615 - $132,677
-734 Reduced 2.19%
32,850 $5.63 Million
Q1 2024

May 09, 2024

SELL
$159.82 - $182.1 $945,015 - $1.08 Million
-5,913 Reduced 14.97%
33,584 $6.12 Million
Q4 2023

Feb 12, 2024

SELL
$137.6 - $154.97 $827,939 - $932,454
-6,017 Reduced 13.22%
39,497 $6.12 Million
Q3 2023

Nov 13, 2023

SELL
$133.59 - $154.65 $84,295 - $97,584
-631 Reduced 1.37%
45,514 $6.78 Million
Q2 2023

Aug 14, 2023

SELL
$132.51 - $164.9 $195,849 - $243,722
-1,478 Reduced 3.1%
46,145 $6.22 Million
Q1 2023

May 08, 2023

SELL
$144.61 - $166.54 $110,048 - $126,736
-761 Reduced 1.57%
47,623 $7.59 Million
Q4 2022

Feb 13, 2023

SELL
$138.31 - $165.87 $729,585 - $874,964
-5,275 Reduced 9.83%
48,384 $7.82 Million
Q3 2022

Nov 07, 2022

SELL
$134.21 - $153.93 $234,062 - $268,453
-1,744 Reduced 3.15%
53,659 $7.2 Million
Q2 2022

Aug 11, 2022

SELL
$137.62 - $174.96 $564,104 - $717,161
-4,099 Reduced 6.89%
55,403 $8.49 Million
Q1 2022

May 02, 2022

SELL
$131.98 - $163.75 $10.6 Million - $13.1 Million
-79,979 Reduced 57.34%
59,502 $9.65 Million
Q4 2021

Feb 11, 2022

BUY
$107.43 - $135.93 $7.19 Million - $9.1 Million
66,929 Added 92.25%
139,481 $18.9 Million
Q3 2021

Nov 12, 2021

SELL
$106.4 - $120.78 $130,659 - $148,317
-1,228 Reduced 1.66%
72,552 $7.83 Million
Q2 2021

Aug 10, 2021

SELL
$105.21 - $117.21 $236,932 - $263,956
-2,252 Reduced 2.96%
73,780 $8.31 Million
Q1 2021

May 06, 2021

SELL
$102.3 - $112.62 $268,128 - $295,177
-2,621 Reduced 3.33%
76,032 $8.23 Million
Q4 2020

Feb 09, 2021

SELL
$80.49 - $108.67 $5,151 - $6,954
-64 Reduced 0.08%
78,653 $8.43 Million
Q3 2020

Nov 06, 2020

BUY
$85.91 - $100.83 $601 - $705
7 Added 0.01%
78,717 $6.89 Million
Q2 2020

Aug 13, 2020

SELL
$73.37 - $98.18 $273,963 - $366,604
-3,734 Reduced 4.53%
78,710 $7.73 Million
Q1 2020

May 11, 2020

SELL
$64.5 - $97.79 $4,257 - $6,454
-66 Reduced 0.08%
82,444 $6.28 Million
Q4 2019

Feb 13, 2020

BUY
$72.13 - $90.25 $4.14 Million - $5.18 Million
57,378 Added 228.31%
82,510 $7.31 Million
Q3 2019

Nov 08, 2019

SELL
$62.98 - $75.72 $4,660 - $5,603
-74 Reduced 0.29%
25,132 $1.9 Million
Q2 2019

Aug 09, 2019

SELL
$65.7 - $83.98 $657 - $839
-10 Reduced 0.04%
25,206 $1.83 Million
Q1 2019

May 14, 2019

SELL
$77.14 - $90.79 $3,779 - $4,448
-49 Reduced 0.19%
25,216 $2.03 Million
Q4 2018

Feb 08, 2019

SELL
$77.85 - $96.01 $11,210 - $13,825
-144 Reduced 0.57%
25,265 $2.33 Million
Q3 2018

Nov 09, 2018

BUY
$88.91 - $98.84 $19,382 - $21,547
218 Added 0.87%
25,409 $2.4 Million
Q2 2018

Aug 10, 2018

SELL
$89.78 - $106.23 $20,200 - $23,901
-225 Reduced 0.89%
25,191 $2.33 Million
Q1 2018

May 08, 2018

BUY
$92.01 - $123.21 $2,484 - $3,326
27 Added 0.11%
25,416 $2.41 Million
Q4 2017

Feb 09, 2018

SELL
$89.56 - $98.21 $13,523 - $14,829
-151 Reduced 0.59%
25,389 $2.46 Million
Q3 2017

Nov 08, 2017

SELL
$69.85 - $89.22 $22,631 - $28,907
-324 Reduced 1.25%
25,540 $2.27 Million
Q2 2017

Aug 15, 2017

BUY
N/A
25,864
25,864 $1.88 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $315B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Roberts Glore & CO Inc Portfolio

Follow Roberts Glore & CO Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Roberts Glore & CO Inc , based on Form 13F filings with the SEC.

News

Stay updated on Roberts Glore & CO Inc with notifications on news.